Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Oklo Inc (OKLO) Price & Performance

Cronos Group IncTrade
Oklo IncTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Oklo Inc — how do they compare? Cronos Group Inc trades at $2.75 (market cap $1.02B), while Oklo Inc trades at $45.2 (market cap $8.05B). The key difference: Oklo Inc is far larger — about 7.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.

CRONOKLO
Market Cap
$1.02B$8.05B
Sector
HealthTechnology
52-Week High
$3.27$174.14
52-Week Low
$1.95$45.58
Enterprise Value
$203.29M$5.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.

Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.

Oklo Inc

OKLO stock trades at $45.81, down 6.22% in the last session, reflecting ongoing volatility. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but faces fundamental challenges with negative ROE (-8.87%) and net income (-$105.66M). Recent DOE approval for the Groves Isotope Test Reactor represents a key regulatory milestone, though cash flow remains heavily dependent on financing activities.

The outlook balances significant growth potential in nuclear energy against substantial execution risks. While analyst targets suggest 98% upside, the company must navigate regulatory hurdles and achieve profitability amid negative earnings trends. The stock's bearish technical signals and high valuation multiples require careful risk assessment by investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.

Read more on OKLO